Basic information
- CAS
108612-45-9- Standard SMILES
CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1- InChIKey
PVLJETXTTWAYEW-UHFFFAOYSA-N- Molecular formula
- C24H25FN6O
- Average molar mass
- 432.5 g/mol
- Monoisotopic mass
- 432.2073876
Overview
Mizolastine is a member of benzimidazoles.
Names & identifiers
- Preferred name
- Mizolastine
- IUPAC
- 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
- English name
- Mizolastine
- Molecular formula
- C24H25FN6O
- Molecular weight
- 432.49
Names & synonyms
Mizolastine108612-45-9MizollenMizolastinaMistalinMizolastinumMizolenZolimSL 85.0324SL-85.03242-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinoneDTXSID5046801
Show more names
MKC 431MistaMineSL 850324MizostatinMizolastine>Mizolastine HClMizolastine inn
244O1F90NADTXCID30268012-[(1-{1-[(4-fluorophenyl)methyl]-1H-1,3-benzodiazol-2-yl}piperidin-4-yl)(methyl)amino]-3,4-dihydropyrimidin-4-one2-((1-(1-((4-fluorophenyl)methyl)-1H-1,3-benzodiazol-2-yl)piperidin-4-yl)(methyl)amino)-3,4-dihydropyrimidin-4-oneRefChem:819015R06AX25ZolistanMKC-431
Database identifiers
- CAS
108612-45-9- PubChem CID
- 65906
- DTXSID
DTXSID5046801- ChEMBL
CHEMBL94454- ChEBI
CHEBI:31857- UNII
- 244O1F90NA
Properties
Computed structural properties
- XLogP
- 3.2
- Topological polar surface area
- 65.8 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 5
- Rotatable bonds
- 5
- Heavy atoms
- 32
- Formal charge
- 0
- Complexity
- 728
Experimental & physicochemical properties
Drugs
Pharmaceuticals -> Respiratory system -> Nasal preparations
Pharmaceuticals
Pharmaceuticals -> Listed in ZINC15
Collision Cross Section203.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID5046801]
Physicochemical properties
- Melting point
- 217 ° · 217°
- Density
- 1.34 · 1.34±0.1 g/cm3(Predicted)
- storage temp.
- Refrigerator
- solubility
- Chloroform (Slightly, Heated), DMSO, Methanol (Slightly, Heated)
- form
- Solid
- pka
- 9.73 · 9.73±0.40(Predicted)
- color
- White
- Merck
- 14 · 14,6221
- InChI
- 1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Safety data
- wgk
- WGK 3
- rtecs
- UW7481284
- hs_code
- 2933.39.9200
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Storage Class
- 11 - Combustible Solids
- Hazard statements
- H302-H312-H332
- Precautionary statements
- P280-P302+P352-P312-P322-P363-P501-P261-P271-P304+P340-P312-P264-P270-P301+P312-P330-P501
Chemistry & industry
Pharmacology
ATC Code
R06AX25
R - Respiratory system
QR - Respiratory system
MeSH Pharmacological Classification
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.
Metabolite PathwaysMizolastine H1-Antihistamine Action
Uses & manufacturing
UsesUse (kg; approx.) in Germany (2009): >25
Applications
DescriptionMizolastine was marketed in Germany and Switzerland as Mizollen for the symptomatic relief of seasonal and perennial allergic rhinoconjunctivitis and urticaria. Mizolastine is a new long-acting, orally active antihistaminic agent with a rapid onset of action ; the two most recent H1 antagonists launched were fexofenadine, metabolite of terfenadine (Sepracor, 1996) and Olopatadine (Kyowa Hakko, 1997). Mizolastine can be prepared in 2 steps from 2-chloro 1- (4-fluorobenzyl)benzimidazole by successive condensations of appropriate amine and thioether. Mizolastine selectively blocks the peripheral H1 receptors (but not the serotonergic, noradrenergic, muscarinic receptors) with a minimal occupancy of brain receptors, and therefore does not elicit any sedative effects. Moreover, Mizolastine does not produce cardiac rhythm disorders which have been associated with certain non-sedating antihistamines in humans.
A highly selective histamine H1-receptor antagonist (with no anticholinergic, antiadrenergic, or antiserotonin activity) for use in the treatment of allergic disorders, especially rhinitis and urticaria.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…